Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
Moleculin Biotech (Nasdaq: MBRX), a late-stage pharmaceutical company focused on developing treatments for hard-to-treat tumors and viruses, has participated in the Virtual Investor 'Top 5 for '25' On-Demand Conference.
During the event, Chairman and CEO Walter Klemp presented the top five reasons why investors and industry colleagues should focus on Moleculin in 2025. The presentation is now available for viewing on the company's website and through the conference platform.
Moleculin Biotech (Nasdaq: MBRX), un'azienda farmaceutica in fase avanzata focalizzata sullo sviluppo di trattamenti per tumori e virus difficili da trattare, ha partecipato alla Conferenza Virtuale per Investitori 'Top 5 per il '25'.
Durante l'evento, il Presidente e CEO Walter Klemp ha presentato i cinque motivi principali per cui investitori e colleghi del settore dovrebbero concentrarsi su Moleculin nel 2025. La presentazione è ora disponibile per la visione sul sito web dell'azienda e attraverso la piattaforma della conferenza.
Moleculin Biotech (Nasdaq: MBRX), una empresa farmacéutica en etapa avanzada centrada en desarrollar tratamientos para tumores y virus difíciles de tratar, ha participado en la Conferencia Virtual para Inversores 'Top 5 para el '25'.
Durante el evento, el Presidente y CEO Walter Klemp presentó las cinco razones principales por las que los inversores y colegas de la industria deberían centrarse en Moleculin en 2025. La presentación ya está disponible para su visualización en el sitio web de la empresa y a través de la plataforma de la conferencia.
몰레큘린 바이오텍 (Nasdaq: MBRX)은 치료하기 어려운 종양과 바이러스에 대한 치료제를 개발하는 데 집중하는 후기 단계의 제약 회사로, '25년을 위한 상위 5개' 가상 투자자 회의에 참여했습니다.
이 행사에서 회장 겸 CEO인 월터 클렘프는 투자자와 업계 동료들이 2025년에 몰레큘린에 집중해야 하는 다섯 가지 주요 이유를 발표했습니다. 발표 내용은 현재 회사 웹사이트와 회의 플랫폼을 통해 시청할 수 있습니다.
Moleculin Biotech (Nasdaq: MBRX), une entreprise pharmaceutique en phase avancée axée sur le développement de traitements pour des tumeurs et des virus difficiles à traiter, a participé à la conférence virtuelle pour investisseurs 'Top 5 pour '25'.
Lors de l'événement, le Président et CEO Walter Klemp a présenté les cinq principales raisons pour lesquelles les investisseurs et les collègues de l'industrie devraient se concentrer sur Moleculin en 2025. La présentation est désormais disponible en visionnage sur le site web de l'entreprise et via la plateforme de la conférence.
Moleculin Biotech (Nasdaq: MBRX), ein Unternehmen der späten Entwicklungsphase, das sich auf die Entwicklung von Behandlungen für schwer zu behandelnde Tumoren und Viren konzentriert, hat an der virtuellen Investorenkonferenz 'Top 5 für '25' teilgenommen.
Während der Veranstaltung präsentierte der Vorsitzende und CEO Walter Klemp die fünf wichtigsten Gründe, warum Investoren und Branchenkollegen 2025 auf Moleculin achten sollten. Die Präsentation ist jetzt auf der Website des Unternehmens und über die Konferenzplattform verfügbar.
- None.
- None.
On-demand video webcast now available here
As part of the event, Walter Klemp, Chairman and Chief Executive Officer of Moleculin, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to Moleculin in 2025.
The on-demand video webcast is now accessible for viewing here and on the Events page in the Investors section of the Company's website (moleculin.com).
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
The Company is initiating the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study is subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.
For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference-302397299.html
SOURCE Moleculin Biotech, Inc.
FAQ
What was discussed at Moleculin Biotech's (MBRX) Virtual Investor Conference in March 2025?
Where can investors access Moleculin's (MBRX) March 2025 investor presentation?
What is Moleculin Biotech's (MBRX) current development stage as of March 2025?
Who presented at Moleculin's (MBRX) Virtual Investor Conference in March 2025?
